Skip to main content
. 2023 Nov 22;13:1235786. doi: 10.3389/fonc.2023.1235786

Figure 2.

Figure 2

Overall survival (OS) and progression-free survival (PFS) with TO or TA regimen. (A) The OS and PFS of all patients. (B) The OS and PFS of patients with BCLC stage (B, C) The OS and PFS of patients with BCLC stage (C) TACE, transarterial chemoembolization; TO, TACE only; TA, TACE combined with anlotinib; BCLC, Barcelona Clinic Liver Cancer.